Mackenzie Financial Corp Invests $70,000 in Health Catalyst, Inc. (NASDAQ:HCAT)

Mackenzie Financial Corp acquired a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 10,922 shares of the company’s stock, valued at approximately $70,000.

Several other hedge funds and other institutional investors have also made changes to their positions in HCAT. The Manufacturers Life Insurance Company lifted its position in Health Catalyst by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock worth $148,000 after purchasing an additional 2,164 shares during the period. Millennium Management LLC lifted its position in Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after purchasing an additional 1,184,131 shares during the period. Daventry Group LP lifted its position in Health Catalyst by 3.9% in the second quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after purchasing an additional 84,178 shares during the period. AQR Capital Management LLC acquired a new stake in Health Catalyst in the second quarter worth approximately $564,000. Finally, First Light Asset Management LLC lifted its position in Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after purchasing an additional 3,221,408 shares during the period. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Health Catalyst

In other news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $6.19, for a total value of $32,243.71. Following the transaction, the chief operating officer now directly owns 150,006 shares of the company’s stock, valued at approximately $928,537.14. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $6.19, for a total transaction of $32,243.71. Following the completion of the transaction, the chief operating officer now directly owns 150,006 shares in the company, valued at $928,537.14. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,362 shares of company stock valued at $256,009 in the last three months. 2.70% of the stock is currently owned by company insiders.

Health Catalyst Stock Up 2.8 %

Shares of NASDAQ:HCAT opened at $7.83 on Wednesday. The company’s fifty day moving average is $7.43 and its two-hundred day moving average is $6.88. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.41. The company has a market cap of $462.24 million, a P/E ratio of -4.23 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.04. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The company had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. During the same period in the previous year, the business earned ($0.21) EPS. The company’s revenue was up 3.7% on a year-over-year basis. Equities research analysts anticipate that Health Catalyst, Inc. will post -0.35 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on HCAT. JPMorgan Chase & Co. upped their target price on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Stephens cut their target price on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating for the company in a research report on Thursday, August 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. Piper Sandler cut their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Finally, Evercore ISI increased their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.58.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.